Aztreonam for injection, USP 1g per vial (Fresenius Kabi, USA)
Aztreonam for injection, USP 1g per vial (Fresenius Kabi, USA) is indicated for use:
- as a single agent in the treatment of infections known or strongly suspected to be due to susceptible gram negative aerobes, such as urinary tract infection, gonorrhoea, etc.
- in combination with other suitable antibiotics to treat serious infections due to problem organisms known or likely to be susceptible to aztreonam.*
- meningitis caused by Haemophilus influenzae or Neisseria meningitidis. Aztreonam for injection, USP 1g per vial (Fresenius Kabi, USA) should not be used alone, but only in combination with other suitable antibiotics, in cases where meningitis is known or presumed to be due to the above organisms. Appropriate therapy should be instituted when results of sensitivity tests are known.
* Some patients with serious Pseudomonas infections may benefit from concurrent use of Aztreonam for injection, USP 1g per vial (Fresenius Kabi, USA) and an aminoglycoside because of synergistic action. However, this enhanced activity is not predictable. If such concurrent therapy is considered in patients with serious infections, susceptibility tests should be performed in vitro to determine the activity of the drugs in combination. Because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics, renal function should be monitored according to the aminoglycoside manufacturer's prescribing information, especially if high dosages of the aminoglycoside are to be used or if therapy is prolonged.
Before instituting treatment with Aztreonam for injection, USP 1g per vial (Fresenius Kabi, USA), appropriate specimens should be obtained for isolation of the causative organism(s) and for determination of susceptibility to aztreonam.
Treatment with Aztreonam for injection, USP 1g per vial (Fresenius Kabi, USA) should normally be initiated on the basis of susceptibility tests, but it may be initiated in the above situations before the results of identification and sensitivity testing of the causative organism become available.
